On July 13, the Department of Health and Human Services (HHS) and the Department of Veterans Affairs (VA) signed a five-year Memorandum of Understanding to coordinate research, clinician training, and health system readiness for rapid-acting psychedelic therapies for veterans with serious mental health conditions, contingent on future Food and Drug Administration (FDA) approval. The announcement came packaged with related actions across the department, including a separate FDA-VA agreement, final FDA guidance on psychedelic clinical trials, and new NIH and ARPA-H funding to study ibogaine for opioid use disorder. Notably for community behavioral health providers, the Health and Resources Services Administration issued a Request for Information on July 14 seeking stakeholder input on workforce training and care-delivery models for safely providing these therapies in community-based settings. The RFI seeks recommendations on clinician education and training, evidence-based care delivery models, and approaches for safely delivering these therapies in community-based settings (including Certified Community Behavioral Health Clinics, Federally Qualified Health Centers, Rural Health Clinics) to help inform future HRSA guidance and technical assistance.